SCHEDULE: Andreessen Horowitz Sells Nautilus Biotechnology Shares

Andreessen Horowitz entities sold 5 million shares of Nautilus Biotechnology in a block trade, reducing their stake.

Summary

• Reporting persons including AH Bio Fund II and Andreessen Horowitz LSV Fund II sold a total of 5,000,000 shares of Nautilus Biotechnology, Inc. common stock.
• The sale occurred on June 2, 2026, in a single block trade at a price of $2.35 per share.
• AH Bio Fund II sold 4,615,974 shares, and Andreessen Horowitz LSV Fund II sold 384,026 shares.
• Following the transaction, the reporting persons collectively beneficially own 12,653,917 shares, representing approximately 9.9% of the issuer's outstanding common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as neutral-to-slightly-negative, as institutional selling often creates short-term downward pressure on share price, though it is a routine part of venture capital lifecycle management.

Positives

• The sale was executed as a single block trade, which typically minimizes market volatility compared to open-market selling.

Negatives

• The divestment of 5 million shares by major institutional investors may signal a reduction in long-term confidence or a portfolio rebalancing strategy.

Risks

• The reduction in ownership by significant venture capital backers could impact market sentiment regarding the company's future growth prospects.

Future Outlook

No specific forward-looking guidance regarding the company's operations was provided in this filing; it is strictly a disclosure of changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that venture capital firms often divest portions of their holdings in biotech companies as they reach certain maturity milestones or to manage fund liquidity, which is a standard practice in the life sciences investment lifecycle.

Comparison to Industry Standards

• The use of block trades for large-scale divestment is a standard institutional practice to avoid excessive slippage in small-to-mid-cap biotech stocks.
• The 9.9% remaining stake indicates that the firm maintains a significant, though reduced, interest in the issuer.

Legal Proceedings

• None disclosed.

Related Party Transactions

• The filing discloses that partners or members of the reporting entities may be entitled to receive dividends or proceeds from the sale of the issuer's shares.

Stakeholder Impact

• Shareholders may experience short-term price volatility due to the large block trade.
• The reduction in ownership by Andreessen Horowitz may be perceived as a signal of a long-term exit strategy.

Next Steps

• Continued monitoring of future Form 4 or Schedule 13D filings to track further divestment or potential exit strategies by the reporting persons.

Key Dates

Recommendation

The sale of 5 million shares by a major institutional investor is a significant event that warrants a hold position until the market absorbs the supply and the company's next operational milestones are clarified.

Keywords

Nautilus Biotechnology, Andreessen Horowitz, Schedule 13D, Block Trade, Insider Selling, Biotech